Developer docs
API playgroundTry for free, no card

Search company profiles

Complete Genomics

Full company profile

uuid000d9rx

Namestring
Complete Genomics
Legal namestring
Complete Genomics, Inc.
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Complete Genomics, Inc. is a U.S.-based genomic sequencing technology company headquartered in San Jose, California, that develops and commercializes the DNBSEQ platform — a DNA nanoball sequencing architecture using rolling circle replication and combinatorial probe-anchor synthesis chemistry — across three throughput tiers (DNBSEQ-G99 benchtop, DNBSEQ-T1+ mid-throughput, and DNBSEQ-T7+ high-throughput at $800,000 per instrument, 48 billion reads in 24 hours). The company's portfolio also includes the Stereo-seq spatial transcriptomics product family (fresh frozen and FFPE formats, single-cell resolution at 0.5 µm with capture areas up to 13 cm × 13 cm), the DNBSEQ-G400 FluoXpert multi-omics system combining sequencing with multiplex immunofluorescence, a full lab-automation suite (SP-NE32/384 extraction, SP-Smart8/100/960 library prep, STP-3000/7000 sample management), and supporting kits, bioinformatics software (MegaBOLT, ZTRON, SAW, StereoMap), and the open-source PanVariants AI variant-calling framework.

The company monetizes through a razor-and-blade model: capital sales of DNBSEQ instruments to research institutions, service providers, and clinical labs, followed by recurring consumables (extraction kits, library prep, sequencing reagents, flow cells) tied to instrument utilization, supplemented by licensing revenue from the CoolMPS technology agreement with Swiss Rockets AG and a certified service-provider network (Gene by Gene, Praxis Genomics, Psomagen, PacGenomics, UCSD CMI, UCLA TCGB, Northwestern, U Colorado, Vancouver Prostate Centre) that delivers DNBSEQ-based sequencing as a service. Customers span academic and research institutions (primary segment), clinical research and diagnostics (via SOPHiA GENETICS and Memorial Sloan Kettering integrations), population-scale genomics programs, agrigenomics, and microbiology applications.

Complete Genomics was founded in 2006, previously listed on NASDAQ (GNOM) prior to delisting, and was controlled by Chinese MGI Tech Co. before entering a definitive agreement in February 2026 to be acquired by Basel-based Swiss Rockets AG, which also exclusively licensed the CoolMPS sequencing chemistry for commercialization outside Asia-Pacific. The repositioning explicitly addresses U.S. Biosecure Act concerns, with the company continuing to operate from San Jose under existing management led by CSO Rade Drmanac and a newly expanded board including former U.S. Ambassador Edward T. McMullen Jr.

Short descriptiontext

Complete Genomics is a U.S.-based (San Jose) genomic sequencing company that develops and sells the DNBSEQ DNA nanoball sequencing platform, Stereo-seq spatial transcriptomics, and lab automation products to academic, clinical, and service-provider customers globally, now under Swiss Rockets AG ownership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA sequencing instruments, spatial transcriptomics, genomic analysis software, sequencing lab automation, NGS consumables reagents
Industry4 codes
1Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
CodeHLAGAIAFPrimaryYes
2Transcriptomics & Gene Expression Profiling Services
CodeHLAGANAEPrimaryNo
3Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
CodeHLAGANAIPrimaryNo
4Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
CodeHLAAAIALPrimaryNo
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
DNA Sequencing Instruments and Genomics Platforms
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Sequencing Instruments
TypeHardware Sales
Description

Sale of DNBSEQ sequencing platforms (G99, T1+, T7+) as capital equipment. Instruments priced at $800,000 for DNBSEQ-T7+ in US market. Represents core hardware revenue from direct sales to research institutions and labs.

completegenomics.com
2Consumables and Reagents
TypeSubscription Recurring
Description

Ongoing revenue from kits and reagents including extraction kits, library preparation kits, sequencing reagents, and flow cells required for DNBSEQ platform operation. Recurring revenue stream tied to instrument utilization.

completegenomics.com
3Technology Licensing
TypeLicensing Royalties
Description

Exclusive licensing of CoolMPS sequencing technology to Swiss Rockets AG for development and commercialization outside Asia-Pacific region. Includes expanded license and supply agreements.

businesswire.com
4Service Provider Network
TypeHardware Sales
Description

Network of certified sequencing service providers offering DNBSEQ-based services. Providers include Gene by Gene, university cores, and commercial labs. Revenue through instrument sales to service providers and potentially reagent supply agreements.

completegenomics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1DNBSEQ-T7+ High-Throughput Sequencer
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

DNBSEQ-T7+ priced at $800,000 in the US and Canada. Delivers 48 billion reads within 24 hours, processing 28,000+ whole genomes per year at $100 per genome cost.

prnewswire.com
2Whole Genome Sequencing Cost
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1 per gigabase or $100 per genome sequencing cost on DNBSEQ-T7+ platform.

prnewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Complete Genomics develops and commercializes the DNBSEQ DNA sequencing platform based on DNA nanoball (DNB) and rolling circle replication chemistry, offering benchtop (G99), mid-throughput (T1+), and high-throughput (T7+) sequencers. The portfolio also includes Stereo-seq spatial transcriptomics, CoolMPS sequencing chemistry, the DNBSEQ-G400 FluoXpert multi-omics system, kits and reagents, bioinformatics software (MegaBOLT, ZTRON), and laboratory automation instruments, sold to research institutions, pharmaceutical companies, clinical research labs, and agrigenomics users.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 73% reduction in genome analysis errors using PanVariants AI-trained models versus standard pipelines
+6 more records
Product overview1 text field

Complete Genomics is a genomic sequencing technology company offering a comprehensive portfolio of DNBSEQ sequencing platforms, spatial transcriptomics solutions, and laboratory automation products. The core product line includes three DNBSEQ sequencers (DNBSEQ-G99 benchtop, DNBSEQ-T1+ mid-throughput, and DNBSEQ-T7+ high-throughput) utilizing proprietary DNA nanoball technology with rolling circle replication. Spatial transcriptomics is enabled through Stereo-seq technology offering true single-cell resolution with multiple chip formats for fresh frozen and FFPE samples, complemented by the DNBSEQ-G400 FluoXpert multi-omics system. Laboratory automation includes sample management systems (STP-3000, STP-7000), nucleic acid extraction instruments (SP-NE32, SP-NE384), and library preparation platforms (SP-Smart8, SP-100, SP-960). Supporting products include extraction and library preparation kits, bioinformatics software (MegaBOLT, ZTRON, SAW, StereoMap), and a global network of certified sequencing service providers. The company was acquired by Swiss Rockets AG in 2026 and offers over 40 compatible third-party products for DNA/RNA sequencing, single-cell analysis, exome sequencing, spatial transcriptomics, epigenetics, oncology, reproductive health, and transplant testing.

Product and service22 records
1DNBSEQ-T7+ High-Throughput Sequencer
CategoryDNA Sequencing Instruments
Description

High-throughput DNBSEQ sequencing platform delivering 48 billion reads within 24 hours across four independent flow cells; processes 28,000+ whole genomes per year with Q40 per-base accuracy at $1 per gigabase or $100 per genome. Sold as capital equipment to large research institutions, pharmaceutical companies, and population-scale genomics programs in the U.S. and Canada.

2DNBSEQ-T1+ Mid-Throughput Sequencer
CategoryDNA Sequencing Instruments
Description

Mid-throughput DNBSEQ Q40 sequencer delivering 25Gb to 1.2Tb output in under 24 hours. All-in-one platform compatible with SOPHiA GENETICS MSK-IMPACT and MSK-ACCESS assays for precision oncology testing. Targeted to clinical and translational labs running cancer genomic profiling, liquid biopsy, and solid tumor testing.

3DNBSEQ-G99 Benchtop Sequencer
CategoryDNA Sequencing Instruments
Description

Benchtop DNBSEQ sequencer delivering up to 48 Gb in less than 12 hours with two independent flow cells that can run at any time. Targeted to smaller labs and clinical settings needing fast, flexible sequencing.

4DNBSEQ-G400 FluoXpert Multi-Omics System
CategoryDNA Sequencing Instruments
Description

Multi-omics system combining genomics, transcriptomics, and proteomics in one instrument; integrates multiplex immunofluorescence staining (up to 24 protein targets) with sequencing capability delivering up to 1440 Gb per run. Targeted to labs requiring combined genomic and proteomic profiling on a single platform.

5Stereo-seq Transcriptomics (FF)
CategorySpatial Transcriptomics
Description

Spatial transcriptomics solution for fresh frozen (FF) tissues achieving true single-cell resolution with 0.22 µm spot diameter and 0.5 µm center-to-center distance, supporting capture areas up to 13 cm x 13 cm. Targeted to academic and translational researchers needing high-resolution spatial gene expression profiling.

6Stereo-seq Transcriptomics Large Chip Design (LCD)
CategorySpatial Transcriptomics
Description

Ultra-wide spatial profiling solution for large tissues and whole organs. Available in 1 cm x 2 cm, 2 cm x 2 cm, and 2 cm x 3 cm chip sizes for centimeter-scale tissue sections at single-cell resolution. Targeted to researchers profiling whole organs or large tissue sections.

7Stereo-seq OMNI (FFPE) Spatial Transcriptomics
CategorySpatial Transcriptomics
Description

Spatial transcriptomics solution for formalin-fixed paraffin-embedded (FFPE) tissue samples enabling whole-transcriptome analysis from archived clinical specimens. Targeted to clinical researchers and translational studies using biobanked FFPE tissues.

8DNA/RNA Extraction Kits
CategoryKits and Reagents
Description

Comprehensive range of DNA and RNA extraction kits (genomic DNA, microbial DNA, RNA, viral DNA/RNA) using superparamagnetic bead technology. Compatible with Complete Genomics SP-NE32, SP-NE384, SP-Smart8, SP-100, and SP-960 automation platforms. Sold as recurring consumables to labs running DNBSEQ workflows.

9Library Preparation Kits
CategoryKits and Reagents
Description

Automation-friendly library preparation kits including DNBSEQ Fast PCR-FREE FS Library Prep Set V2.0, Fast FS Library Prep Set, Fast RNA Library Prep Set, and Library Conversion Kits for third-party kit compatibility. Sold as recurring consumables to DNBSEQ platform users.

10MegaBOLT Bioinformatics Workstation
CategoryBioinformatics Software
Description

Bioinformatics accelerator workstation/server for fast secondary analysis of DNBSEQ sequencing data, designed to speed up alignment and variant calling workflows. Sold to labs running high-throughput DNBSEQ production pipelines.

11ZTRON Lite and Pro Data Management and Analysis Platform
CategoryBioinformatics Software
Description

Integrated hardware and software solutions for sequencing data management and bioinformatics analysis, available in Lite and Pro configurations. Targeted to labs requiring integrated storage, management, and analysis of DNBSEQ data.

12Go Optical STOmics Microscope
CategorySpatial Transcriptomics Imaging
Description

STOmics microscope designed specifically for Stereo-seq spatial transcriptomics workflows with 12-megapixel resolution imaging, motorized XY travel of 100 mm x 70 mm, and auto-focus capability scanning 10 mm x 10 mm chips in under 70 seconds. Targeted to Stereo-seq users needing high-resolution tissue imaging.

13STP-3000 Automated Sample Management System
CategoryLaboratory Automation
Description

Automated sample accessioning system that transfers 96 samples from sealed collection tubes to 96-well microplates in 40 minutes with automatic de/re-capping. Targeted to labs needing standardized sample intake for DNBSEQ workflows.

14STP-7000 High-Throughput Sample Management System
CategoryLaboratory Automation
Description

Highest-throughput automated liquid sample transfer system with freestanding, fully enclosed, HEPA-filtered design for processing large sample volumes. Targeted to production-scale genomics labs.

15SP-NE32 Nucleic Acid Extraction System
CategoryLaboratory Automation
Description

Nucleic acid extraction system processing 32 samples per run for DNA and RNA extraction from blood, tissue, and microbial samples. Targeted to small-to-mid-sized genomics labs.

16SP-NE384 High-Throughput Nucleic Acid Extraction System
CategoryLaboratory Automation
Description

High-throughput nucleic acid extraction system processing 384 samples for genomic DNA, microbial DNA, and viral nucleic acid extraction. Targeted to production-scale genomics and clinical labs.

17SP-Smart8 Benchtop Library Preparation System
CategoryLaboratory Automation
Description

Compact benchtop library preparation system supporting 8 samples for automated NGS library preparation. Targeted to small labs needing standardized library prep.

18SP-100 Mid-Throughput Library Preparation System
CategoryLaboratory Automation
Description

Mid-throughput automated library preparation system processing 8–32 samples per run with 40–80 minute assay times. Targeted to mid-sized genomics labs.

19SP-960 High-Throughput Library Preparation System
CategoryLaboratory Automation
Description

High-throughput automated library preparation system processing 192 samples per 60 minutes for large-scale sequencing projects. Targeted to production genomics labs.

20PanVariants AI-Driven Variant Calling Framework
CategoryBioinformatics Software
Description

Open-source AI-driven variant calling framework for DNBSEQ sequencing data demonstrating up to 73% reduction in genome analysis errors versus standard industry pipelines, available across T1+, T7, and T7+ platforms. Targeted to genomic researchers running secondary analysis on DNBSEQ data.

21Sequencing Service Provider Network
CategorySequencing Services
Description

Network of certified sequencing service providers offering access to DNBSEQ platforms including Gene by Gene, University of Colorado Cancer Center Genomics Shared Resource, Northwestern NUSeq Core Facility, Praxis Genomics, Psomagen, UCSD Center for Microbiome Innovation, UCLA TCGB, Vancouver Prostate Centre, and others. Enables researchers without capital equipment to access DNBSEQ sequencing services.

22Spatial Certified Service Provider Network
CategorySpatial Transcriptomics Services
Description

Certified service providers trained on Stereo-seq and DNBSEQ spatial workflows including Gene by Gene, Admera Health, Clemson University, UCSD CMI, UNC Chapel Hill HTSF, UCLA TCGB, and Vancouver Prostate Centre. Provides researchers with outsourced access to spatial transcriptomics services.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-11
Description

Collaboration to integrate SOPHiA GENETICS' MSK-IMPACT and MSK-ACCESS assays (developed with Memorial Sloan Kettering Cancer Center) with Complete Genomics' DNBSEQ-T1+ sequencing platform. Provides laboratories with end-to-end sample-to-report workflow for liquid biopsy and solid tumor testing. Joint evaluations demonstrated concordant variant calls with lower background noise and reduced turnaround times.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-29
Description

Exclusive licensing agreement for CoolMPS sequencing technology from MGI Tech to Swiss Rockets AG and Complete Genomics for development and commercialization outside Asia-Pacific and Greater China. Covers USA, Europe, Latam, Africa, and Central Asia regions with option to expand into Asia-Pacific.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Strategic partnership announced at ASHG 2025 for collaborative development and research initiatives.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-10-14
Description

Partnership announced at ASHG 2025 for integration of Bio-Rad products with Complete Genomics sequencing platforms.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-14
Description

STOmics provides Stereo-seq spatial transcriptomics products including Transcriptomics kits, Go Optical microscope, and certified service provider program for spatial solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-13
Description

Gene by Gene announced as Complete Genomics' newest sequencing service provider at ASHG 2025, offering WGS and consulting services using DNBSEQ-G400 and DNBSEQ-T7 platforms.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-04-28
Description

Partnership to integrate sequencing and analysis platforms for enhanced clinical genomics workflows.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-25
Description

Commercial partnership to offer Human Cell Atlas members access to Stereo-seq spatial transcriptomics technology at NextGen Omics & Spatial Biology Conference.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dominant NGS sequencing platform provider with the broadest installed base and reagent ecosystem. Direct competitor across short-read sequencing applications where Complete Genomics competes on cost-per-genome and accuracy.

TypeEmerging player
Description

High-throughput low-cost sequencing competitor pursuing a similar $100/genome cost target. Most direct head-to-head on population-scale sequencing economics where Complete Genomics positions the T7+.

TypeDirect peer
Description

Nanopore-based long-read sequencing competitor. Competes in applications requiring long-read data; Complete Genomics' cWGS phasing solution is positioned against Oxford Nanopore's traditional strengths.

TypeEmerging player
Description

Challenger sequencing platform (AVITI) targeting the mid-throughput segment with competing chemistry. Direct head-to-head competitor with DNBSEQ-T1+ for benchtop and clinical research customers.

TypeEmerging player
Description

Multi-omics sequencing platform (G4) competing in the benchtop/mid-throughput segment. Targets similar academic and clinical research customers as Complete Genomics' lower-throughput instruments.

TypeDirect peer
Description

Long-read sequencing platform provider (PacBio Revio, Onso). Competes at the high-accuracy end of sequencing and complements Complete Genomics' phased WGS offering with DNBSEQ Complete WGS.

TypeRegional player
Description

China-based genomic services and sequencing platform provider, co-targeted with Complete Genomics under the Biosecure Act. Comparable DNBSEQ-based service offering but primarily operates in Asia-Pacific rather than competing directly in US markets.

TypeEmerging player
Description

Single-cell and spatial biology platform with overlapping spatial transcriptomics territory through Visium HD/Xenium. Competes with Stereo-seq for spatial omics research dollars while also integrating as a compatible upstream for DNBSEQ.

TypeBroad incumbent
Description

Diversified life sciences tools giant offering Ion Torrent semiconductor sequencing alongside broader analytical instruments and reagents. Competes in mid-throughput sequencing segments relevant to DNBSEQ-T1+ positioning.

TypeDirect peer
Description

China-based developer of DNBSEQ sequencing technology and Complete Genomics' former parent. Closest technical peer given shared DNA nanoball technology base, though now operates as a licensor/supplier relationship.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration38 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Complete Genomics

DNA Sequencing Instruments and Genomics Platformscompletegenomics.com

Complete Genomics is a U.S.-based (San Jose) genomic sequencing company that develops and sells the DNBSEQ DNA nanoball sequencing platform, Stereo-seq spatial transcriptomics, and lab automation products to academic, clinical, and service-provider customers globally, now under Swiss Rockets AG ownership.

What Complete Genomics does

Complete Genomics, Inc. is a U.S.-based genomic sequencing technology company headquartered in San Jose, California, that develops and commercializes the DNBSEQ platform — a DNA nanoball sequencing architecture using rolling circle replication and combinatorial probe-anchor synthesis chemistry — across three throughput tiers (DNBSEQ-G99 benchtop, DNBSEQ-T1+ mid-throughput, and DNBSEQ-T7+ high-throughput at $800,000 per instrument, 48 billion reads in 24 hours). The company's portfolio also includes the Stereo-seq spatial transcriptomics product family (fresh frozen and FFPE formats, single-cell resolution at 0.5 µm with capture areas up to 13 cm × 13 cm), the DNBSEQ-G400 FluoXpert multi-omics system combining sequencing with multiplex immunofluorescence, a full lab-automation suite (SP-NE32/384 extraction, SP-Smart8/100/960 library prep, STP-3000/7000 sample management), and supporting kits, bioinformatics software (MegaBOLT, ZTRON, SAW, StereoMap), and the open-source PanVariants AI variant-calling framework.

The company monetizes through a razor-and-blade model: capital sales of DNBSEQ instruments to research institutions, service providers, and clinical labs, followed by recurring consumables (extraction kits, library prep, sequencing reagents, flow cells) tied to instrument utilization, supplemented by licensing revenue from the CoolMPS technology agreement with Swiss Rockets AG and a certified service-provider network (Gene by Gene, Praxis Genomics, Psomagen, PacGenomics, UCSD CMI, UCLA TCGB, Northwestern, U Colorado, Vancouver Prostate Centre) that delivers DNBSEQ-based sequencing as a service. Customers span academic and research institutions (primary segment), clinical research and diagnostics (via SOPHiA GENETICS and Memorial Sloan Kettering integrations), population-scale genomics programs, agrigenomics, and microbiology applications.

Complete Genomics was founded in 2006, previously listed on NASDAQ (GNOM) prior to delisting, and was controlled by Chinese MGI Tech Co. before entering a definitive agreement in February 2026 to be acquired by Basel-based Swiss Rockets AG, which also exclusively licensed the CoolMPS sequencing chemistry for commercialization outside Asia-Pacific. The repositioning explicitly addresses U.S. Biosecure Act concerns, with the company continuing to operate from San Jose under existing management led by CSO Rade Drmanac and a newly expanded board including former U.S. Ambassador Edward T. McMullen Jr.

Complete Genomics firmographics

Firmographics
Name
Complete Genomics
Legal name
Complete Genomics, Inc.
Website
https://completegenomics.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
251–500 employees
Short description
Complete Genomics is a U.S.-based (San Jose) genomic sequencing company that develops and sells the DNBSEQ DNA nanoball sequencing platform, Stereo-seq spatial transcriptomics, and lab automation products to academic, clinical, and service-provider customers globally, now under Swiss Rockets AG ownership.
Ownership category
akta.pro rank

Complete Genomics industry classification

Industry
Product category
DNA Sequencing Instruments and Genomics Platforms
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
akta.pro secondary industries
Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

  • DNA sequencing instruments
  • Spatial transcriptomics
  • Genomic analysis software
  • Sequencing lab automation
  • NGS consumables reagents

Where Complete Genomics is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Complete Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Sequencing Instruments: Sale of DNBSEQ sequencing platforms (G99, T1+, T7+) as capital equipment. Instruments priced at $800,000 for DNBSEQ-T7+ in US market. Represents core hardware revenue from direct sales to research institutions and labs.
  2. Consumables and Reagents: Ongoing revenue from kits and reagents including extraction kits, library preparation kits, sequencing reagents, and flow cells required for DNBSEQ platform operation. Recurring revenue stream tied to instrument utilization.
  3. Technology Licensing: Exclusive licensing of CoolMPS sequencing technology to Swiss Rockets AG for development and commercialization outside Asia-Pacific region. Includes expanded license and supply agreements.
  4. Service Provider Network: Network of certified sequencing service providers offering DNBSEQ-based services. Providers include Gene by Gene, university cores, and commercial labs. Revenue through instrument sales to service providers and potentially reagent supply agreements.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractDNBSEQ-T7+ High-Throughput Sequencer
Unit PricingPay-as-you-goWhole Genome Sequencing Cost

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Complete Genomics product offering

Product offering

Core offering

Complete Genomics develops and commercializes the DNBSEQ DNA sequencing platform based on DNA nanoball (DNB) and rolling circle replication chemistry, offering benchtop (G99), mid-throughput (T1+), and high-throughput (T7+) sequencers. The portfolio also includes Stereo-seq spatial transcriptomics, CoolMPS sequencing chemistry, the DNBSEQ-G400 FluoXpert multi-omics system, kits and reagents, bioinformatics software (MegaBOLT, ZTRON), and laboratory automation instruments, sold to research institutions, pharmaceutical companies, clinical research labs, and agrigenomics users.

Product overview

Complete Genomics is a genomic sequencing technology company offering a comprehensive portfolio of DNBSEQ sequencing platforms, spatial transcriptomics solutions, and laboratory automation products. The core product line includes three DNBSEQ sequencers (DNBSEQ-G99 benchtop, DNBSEQ-T1+ mid-throughput, and DNBSEQ-T7+ high-throughput) utilizing proprietary DNA nanoball technology with rolling circle replication. Spatial transcriptomics is enabled through Stereo-seq technology offering true single-cell resolution with multiple chip formats for fresh frozen and FFPE samples, complemented by the DNBSEQ-G400 FluoXpert multi-omics system. Laboratory automation includes sample management systems (STP-3000, STP-7000), nucleic acid extraction instruments (SP-NE32, SP-NE384), and library preparation platforms (SP-Smart8, SP-100, SP-960). Supporting products include extraction and library preparation kits, bioinformatics software (MegaBOLT, ZTRON, SAW, StereoMap), and a global network of certified sequencing service providers. The company was acquired by Swiss Rockets AG in 2026 and offers over 40 compatible third-party products for DNA/RNA sequencing, single-cell analysis, exome sequencing, spatial transcriptomics, epigenetics, oncology, reproductive health, and transplant testing.

Differentiator

Problem solved

Functional benefit

Products and services

  • DNBSEQ-T7+ High-Throughput Sequencer High-throughput DNBSEQ sequencing platform delivering 48 billion reads within 24 hours across four independent flow cells; processes 28,000+ whole genomes per year with Q40 per-base accuracy at $1 per gigabase or $100 per genome. Sold as capital equipment to large research institutions, pharmaceutical companies, and population-scale genomics programs in the U.S. and Canada.
  • DNBSEQ-T1+ Mid-Throughput Sequencer Mid-throughput DNBSEQ Q40 sequencer delivering 25Gb to 1.2Tb output in under 24 hours. All-in-one platform compatible with SOPHiA GENETICS MSK-IMPACT and MSK-ACCESS assays for precision oncology testing. Targeted to clinical and translational labs running cancer genomic profiling, liquid biopsy, and solid tumor testing.
  • DNBSEQ-G99 Benchtop Sequencer Benchtop DNBSEQ sequencer delivering up to 48 Gb in less than 12 hours with two independent flow cells that can run at any time. Targeted to smaller labs and clinical settings needing fast, flexible sequencing.
  • DNBSEQ-G400 FluoXpert Multi-Omics System Multi-omics system combining genomics, transcriptomics, and proteomics in one instrument; integrates multiplex immunofluorescence staining (up to 24 protein targets) with sequencing capability delivering up to 1440 Gb per run. Targeted to labs requiring combined genomic and proteomic profiling on a single platform.
  • Stereo-seq Transcriptomics (FF) Spatial transcriptomics solution for fresh frozen (FF) tissues achieving true single-cell resolution with 0.22 µm spot diameter and 0.5 µm center-to-center distance, supporting capture areas up to 13 cm x 13 cm. Targeted to academic and translational researchers needing high-resolution spatial gene expression profiling.
  • Stereo-seq Transcriptomics Large Chip Design (LCD) Ultra-wide spatial profiling solution for large tissues and whole organs. Available in 1 cm x 2 cm, 2 cm x 2 cm, and 2 cm x 3 cm chip sizes for centimeter-scale tissue sections at single-cell resolution. Targeted to researchers profiling whole organs or large tissue sections.
  • Stereo-seq OMNI (FFPE) Spatial Transcriptomics Spatial transcriptomics solution for formalin-fixed paraffin-embedded (FFPE) tissue samples enabling whole-transcriptome analysis from archived clinical specimens. Targeted to clinical researchers and translational studies using biobanked FFPE tissues.
  • DNA/RNA Extraction Kits Comprehensive range of DNA and RNA extraction kits (genomic DNA, microbial DNA, RNA, viral DNA/RNA) using superparamagnetic bead technology. Compatible with Complete Genomics SP-NE32, SP-NE384, SP-Smart8, SP-100, and SP-960 automation platforms. Sold as recurring consumables to labs running DNBSEQ workflows.
  • Library Preparation Kits Automation-friendly library preparation kits including DNBSEQ Fast PCR-FREE FS Library Prep Set V2.0, Fast FS Library Prep Set, Fast RNA Library Prep Set, and Library Conversion Kits for third-party kit compatibility. Sold as recurring consumables to DNBSEQ platform users.
  • MegaBOLT Bioinformatics Workstation Bioinformatics accelerator workstation/server for fast secondary analysis of DNBSEQ sequencing data, designed to speed up alignment and variant calling workflows. Sold to labs running high-throughput DNBSEQ production pipelines.
  • ZTRON Lite and Pro Data Management and Analysis Platform Integrated hardware and software solutions for sequencing data management and bioinformatics analysis, available in Lite and Pro configurations. Targeted to labs requiring integrated storage, management, and analysis of DNBSEQ data.
  • Go Optical STOmics Microscope STOmics microscope designed specifically for Stereo-seq spatial transcriptomics workflows with 12-megapixel resolution imaging, motorized XY travel of 100 mm x 70 mm, and auto-focus capability scanning 10 mm x 10 mm chips in under 70 seconds. Targeted to Stereo-seq users needing high-resolution tissue imaging.
  • STP-3000 Automated Sample Management System Automated sample accessioning system that transfers 96 samples from sealed collection tubes to 96-well microplates in 40 minutes with automatic de/re-capping. Targeted to labs needing standardized sample intake for DNBSEQ workflows.
  • STP-7000 High-Throughput Sample Management System Highest-throughput automated liquid sample transfer system with freestanding, fully enclosed, HEPA-filtered design for processing large sample volumes. Targeted to production-scale genomics labs.
  • SP-NE32 Nucleic Acid Extraction System Nucleic acid extraction system processing 32 samples per run for DNA and RNA extraction from blood, tissue, and microbial samples. Targeted to small-to-mid-sized genomics labs.
  • SP-NE384 High-Throughput Nucleic Acid Extraction System High-throughput nucleic acid extraction system processing 384 samples for genomic DNA, microbial DNA, and viral nucleic acid extraction. Targeted to production-scale genomics and clinical labs.
  • SP-Smart8 Benchtop Library Preparation System Compact benchtop library preparation system supporting 8 samples for automated NGS library preparation. Targeted to small labs needing standardized library prep.
  • SP-100 Mid-Throughput Library Preparation System Mid-throughput automated library preparation system processing 8–32 samples per run with 40–80 minute assay times. Targeted to mid-sized genomics labs.
  • SP-960 High-Throughput Library Preparation System High-throughput automated library preparation system processing 192 samples per 60 minutes for large-scale sequencing projects. Targeted to production genomics labs.
  • PanVariants AI-Driven Variant Calling Framework Open-source AI-driven variant calling framework for DNBSEQ sequencing data demonstrating up to 73% reduction in genome analysis errors versus standard industry pipelines, available across T1+, T7, and T7+ platforms. Targeted to genomic researchers running secondary analysis on DNBSEQ data.
  • Sequencing Service Provider Network Network of certified sequencing service providers offering access to DNBSEQ platforms including Gene by Gene, University of Colorado Cancer Center Genomics Shared Resource, Northwestern NUSeq Core Facility, Praxis Genomics, Psomagen, UCSD Center for Microbiome Innovation, UCLA TCGB, Vancouver Prostate Centre, and others. Enables researchers without capital equipment to access DNBSEQ sequencing services.
  • Spatial Certified Service Provider Network Certified service providers trained on Stereo-seq and DNBSEQ spatial workflows including Gene by Gene, Admera Health, Clemson University, UCSD CMI, UNC Chapel Hill HTSF, UCLA TCGB, and Vancouver Prostate Centre. Provides researchers with outsourced access to spatial transcriptomics services.

Quantifiable outcome

  • 73% reduction in genome analysis errors using PanVariants AI-trained models versus standard pipelines
  • +6 more outcomes

Companies that use Complete Genomics

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles6 records

Complete Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration38 records

AI capability9 records

Feature6 records

Complete Genomics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and major.

  • SOPHiA GENETICScoreTechnology or Integration · 11 November 2025Collaboration to integrate SOPHiA GENETICS' MSK-IMPACT and MSK-ACCESS assays (developed with Memorial Sloan Kettering Cancer Center) with Complete Genomics' DNBSEQ-T1+ sequencing platform. Provides laboratories with end-to-end sample-to-report workflow for liquid biopsy and solid tumor testing. Joint evaluations demonstrated concordant variant calls with lower background noise and reduced turnaround times.
  • MGI TechcoreTechnology or Integration · 29 October 2025Exclusive licensing agreement for CoolMPS sequencing technology from MGI Tech to Swiss Rockets AG and Complete Genomics for development and commercialization outside Asia-Pacific and Greater China. Covers USA, Europe, Latam, Africa, and Central Asia regions with option to expand into Asia-Pacific.
  • Mayo ClinicmajorStrategic or Co-development Partner · 14 October 2025Strategic partnership announced at ASHG 2025 for collaborative development and research initiatives.
  • Bio-RadmajorTechnology or Integration · 14 October 2025Partnership announced at ASHG 2025 for integration of Bio-Rad products with Complete Genomics sequencing platforms.
  • STOmicscoreTechnology or Integration · 14 October 2025STOmics provides Stereo-seq spatial transcriptomics products including Transcriptomics kits, Go Optical microscope, and certified service provider program for spatial solutions.
  • Gene by GenecoreChannel Partner/ Reseller/ Distributor · 13 October 2025Gene by Gene announced as Complete Genomics' newest sequencing service provider at ASHG 2025, offering WGS and consulting services using DNBSEQ-G400 and DNBSEQ-T7 platforms.
  • VelseramajorTechnology or Integration · 28 April 2025Partnership to integrate sequencing and analysis platforms for enhanced clinical genomics workflows.
  • Human Cell AtlasmajorStrategic or Co-development Partner · 25 March 2025Commercial partnership to offer Human Cell Atlas members access to Stereo-seq spatial transcriptomics technology at NextGen Omics & Spatial Biology Conference.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Complete Genomics competitors and assessment

Company assessment

Direct peers

  • Illumina: Dominant NGS sequencing platform provider with the broadest installed base and reagent ecosystem. Direct competitor across short-read sequencing applications where Complete Genomics competes on cost-per-genome and accuracy.
  • Oxford Nanopore Technologies: Nanopore-based long-read sequencing competitor. Competes in applications requiring long-read data; Complete Genomics' cWGS phasing solution is positioned against Oxford Nanopore's traditional strengths.
  • Pacific Biosciences: Long-read sequencing platform provider (PacBio Revio, Onso). Competes at the high-accuracy end of sequencing and complements Complete Genomics' phased WGS offering with DNBSEQ Complete WGS.
  • MGI Tech: China-based developer of DNBSEQ sequencing technology and Complete Genomics' former parent. Closest technical peer given shared DNA nanoball technology base, though now operates as a licensor/supplier relationship.

Emerging players

  • Ultima Genomics: High-throughput low-cost sequencing competitor pursuing a similar $100/genome cost target. Most direct head-to-head on population-scale sequencing economics where Complete Genomics positions the T7+.
  • Element Biosciences: Challenger sequencing platform (AVITI) targeting the mid-throughput segment with competing chemistry. Direct head-to-head competitor with DNBSEQ-T1+ for benchtop and clinical research customers.
  • Singular Genomics: Multi-omics sequencing platform (G4) competing in the benchtop/mid-throughput segment. Targets similar academic and clinical research customers as Complete Genomics' lower-throughput instruments.
  • 10x Genomics: Single-cell and spatial biology platform with overlapping spatial transcriptomics territory through Visium HD/Xenium. Competes with Stereo-seq for spatial omics research dollars while also integrating as a compatible upstream for DNBSEQ.

Regional players

  • BGI Genomics: China-based genomic services and sequencing platform provider, co-targeted with Complete Genomics under the Biosecure Act. Comparable DNBSEQ-based service offering but primarily operates in Asia-Pacific rather than competing directly in US markets.

Broad incumbents

  • Thermo Fisher Scientific (Ion Torrent): Diversified life sciences tools giant offering Ion Torrent semiconductor sequencing alongside broader analytical instruments and reagents. Competes in mid-throughput sequencing segments relevant to DNBSEQ-T1+ positioning.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Complete Genomics social profiles

Digital presence

Complete Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Complete Genomics leadership team

Management profile

Number of profiles

Profiles3 records

Complete Genomics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Complete Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Complete Genomics

What does Complete Genomics do?

Complete Genomics develops and commercializes the DNBSEQ DNA sequencing platform based on DNA nanoball (DNB) and rolling circle replication chemistry, offering benchtop (G99), mid-throughput (T1+), and high-throughput (T7+) sequencers. The portfolio also includes Stereo-seq spatial transcriptomics, CoolMPS sequencing chemistry, the DNBSEQ-G400 FluoXpert multi-omics system, kits and reagents, bioinformatics software (MegaBOLT, ZTRON), and laboratory automation instruments, sold to research institutions, pharmaceutical companies, clinical research labs, and agrigenomics users.

Is Complete Genomics a public or private company?

Complete Genomics is a private company. It is classified as corporate owned and is currently operating.

When was Complete Genomics founded?

Complete Genomics was founded in 2006. It employs 251 to 500 people.

Where is Complete Genomics based?

Complete Genomics is headquartered in Mountain View, United States, in the North America region.

How does Complete Genomics make money?

Four revenue lines are on record. Sequencing Instruments are the primary driver. The others are consumables and Reagents, technology Licensing and service Provider Network.

Who are Complete Genomics's main competitors?

Direct peers on record are Illumina, Oxford Nanopore Technologies, Pacific Biosciences and MGI Tech. Emerging players are Ultima Genomics, Element Biosciences, Singular Genomics and 10x Genomics. BGI Genomics is listed as a regional player. Thermo Fisher Scientific (Ion Torrent) is listed as a broad incumbent.

Does Complete Genomics have an API?

No public API is recorded for Complete Genomics.

What industry is Complete Genomics in?

Complete Genomics's product category is DNA Sequencing Instruments and Genomics Platforms. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizComplete Genomics Names Lauren Selig to Board Ahead of Swiss Rockets AcquisitionComplete Genomics has appointed Lauren Selig to its Board of Directors, effective upon completion of its acquisition by Swiss Rockets AG. Selig's appointment aims to enhance Complete Genomics' strategic direction as it prepares to operate independently in the U.S. following the acquisition, which remains subject to U.S. regulatory approval. The acquisition has already received approval from various stakeholders, positioning Complete Genomics for potential growth in genomics and precision medicine.Investing.comComplete Genomics appoints Lauren Selig to board of directors By Investing.comComplete Genomics announced the appointment of Lauren Selig to its board of directors, an action effective upon the closing of its acquisition by Swiss Rockets AG. The transaction has received approval from MGI Tech shareholders and Chinese regulatory authorities but remains subject to clearance by the Committee on Foreign Investment in the United States. Complete Genomics is a U.S.-based DNA sequencing provider, while Swiss Rockets AG operates as a biotech incubator.Stock TitanComplete Genomics to Add Lauren Selig to Board at CloseComplete Genomics announced the appointment of Lauren Selig to its board of directors, effective upon the closing of its pending acquisition by Swiss Rockets AG. The transaction has received approval from shareholders and Chinese regulatory authorities but remains subject to clearance by the Committee on Foreign Investment in the United States (CFIUS).BioSpaceComplete Genomics Appoints Lauren Selig to Board of DirectorsComplete Genomics appointed Lauren Selig to its board of directors, effective upon closing of its pending acquisition by Swiss Rockets AG. Selig, a film producer and investor, brings experience from Rocketman and Hacksaw Ridge. The appointment continues the company's board expansion as it prepares for growth.The National Law ReviewDOW Adds 65 New Entitities to 1260H List, Including Chinese ComapThe Department of War updated its 1260H List on June 8, 2026, adding approximately 65 Chinese entities including electric vehicle manufacturers, solar equipment makers, technology companies like Alibaba, and biotechnology firms such as WuXi AppTec and Complete Genomics. The update triggers significant procurement restrictions for government contractors, including prohibitions on contracting with listed entities and companies that use their products, with restrictions taking effect June 30, 2026 and 2027. Biotechnology companies on the list may face additional consequences under the BIOSECURE Act, which prohibits federal agencies from procuring biotechnology equipment or services from designated 'biotechnology companies of concern' and could take full effect by mid-to-late 2028.Grand View ResearchHigh-throughput Genomic Screening For Preventive Healthcare Market Report, 2026-2033The global high-throughput genomic screening market for preventive healthcare is projected to grow from USD 846.1 million in 2025 to USD 2,169.7 million by 2033, driven by the shift toward personalized prevention and technological advancements in next-generation sequencing. Key industry developments include strategic acquisitions such as QIAGEN's purchase of Genoox and Swiss Rockets AG's acquisition of Complete Genomics to enhance AI-powered analysis capabilities. Market expansion is further supported by increasing consumer demand for direct-to-consumer insights and the integration of genomic testing into national healthcare systems like the UK's NHS.citybizComplete Genomics Names Former Ambassador Edward McMullen to BoardComplete Genomics has appointed former U.S. Ambassador Edward T. McMullen Jr. to its Board of Directors, with the appointment effective upon closing of the company's pending acquisition by Swiss Rockets AG. McMullen, who served as U.S. ambassador to Switzerland and Liechtenstein from 2017 to 2021, brings over 30 years of experience in diplomacy, foreign direct investment, public policy, and international business. The appointment reflects the company's focus on strengthening its global market access and policy alignment as it expands U.S. operations and develops its genomics technology platform for research and healthcare applications.PR NewswireComplete Genomics Appoints Former U.S. Ambassador Edward T. McMullen Jr. to Board of DirectorsComplete Genomics announced the appointment of former U.S. Ambassador Edward T. McMullen Jr. to its Board of Directors, effective upon the closing of the company's pending acquisition by Swiss Rockets AG. McMullen, who served as ambassador to Switzerland and Liechtenstein from 2017 to 2021, brings over three decades of experience in diplomacy, public policy, and international business, which the company says will support its expansion of U.S. manufacturing and customer support operations. The appointment is part of Complete Genomics' strategy to advance genomic innovation while strengthening its global presence and cross-border investment capabilities.The Manila TimesNew study demonstrates up to 73% reduction in genome analysis errors using AI-trained models versus standard approachesComplete Genomics announced study results showing that AI-trained variant calling models can reduce genome analysis errors by up to 73% when applied to DNBSEQ sequencing data compared to standard industry pipelines. The study demonstrated high accuracy across multiple datasets from T1+, T7, and T7+ platforms, with performance on complex genomic regions approaching that of long-read sequencing technologies. The company is making the PanVariants AI-driven analysis framework available as an open-source resource to support further innovation across the genomics community.PR NewswireNew study demonstrates up to 73% reduction in genome analysis errors using AI-trained models versus standard approachesComplete Genomics announced results from a study demonstrating that AI-trained variant calling models can reduce genome analysis errors by up to 73% when applied to DNBSEQ sequencing data compared to standard industry pipelines. The research, conducted across multiple sequencing platforms (T1+, T7, T7+), showed consistent high accuracy for SNVs and indels, with performance in complex genomic regions approaching that of long-read sequencing technologies. Complete Genomics is releasing PanVariants, the AI-driven analysis framework, as an open-source resource to support broader adoption in research and translational settings.